Expert Council Resolution “The place of quifenadine in the treatment of allergic diseases and the classification of antihistamines”

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Antihistamines are the most commonly prescribed pharmacological therapy for allergic diseases, the prevalence of which reaches 30% of the population in the modern world, affecting people of all ages. The appointment of antihistamines for allergic rhinitis and urticaria is the first line of therapy, allowing in most cases to achieve control of symptoms. Existing antihistamines are usually divided into I and II generation antihistamines. Hifenadine, synthesized in the Acad. M.D. Mashkovsky laboratory in the 1970s, was historically assigned to the 1st generation antihistamines, however, according to its characteristics (low risk of sedation, absence of tachyphylaxis, antiserotonin effect, activation of diamine oxidase), it rather belongs to the 2nd generation antihistamines. This discrepancy raises questions and may confuse clinicians when prescribing the drug. In this regard, an Expert Council with the purpose to define the pharmacological properties of hifenadine, its clinical efficacy, tolerability and safety, which determine the place of the drug in the classification of antihistamines and the treatment of allergic diseases was held.

Texto integral

Acesso é fechado

Sobre autores

Natalya Nenasheva

Russian Medical Academy of Continuous Professional Education

Autor responsável pela correspondência
Email: 1444031@gmail.com
ORCID ID: 0000-0002-3162-2510
Scopus Author ID: 57201763856

Dr. Sсi. (Med.), Professor, Head of the Department of Allergology and Immunology

Rússia, Moscow

N. Ilyina

State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency

Email: 1444031@gmail.com
ORCID ID: 0000-0002-3556-969X
Rússia, Moscow

I. Gushchin

State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency

Email: 1444031@gmail.com
ORCID ID: 0000-0002-4465-6509
Rússia, Moscow

I. Danilycheva

State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency

Email: 1444031@gmail.com
ORCID ID: 0000-0002-8279-2173
Rússia, Moscow

I. Zakharova

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID ID: 0000-0003-4200-4598
Rússia, Moscow

S. Zyryanov

Peoples’ Friendship University of Russia

Email: 1444031@gmail.com
ORCID ID: 0000-0002-6348-6867
Rússia, Moscow

O. Kurbacheva

State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency

Email: 1444031@gmail.com
ORCID ID: 0000-0003-3250-0694
Rússia, Moscow

Yu. Smolkin

Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency

Email: 1444031@gmail.com
ORCID ID: 0000-0001-7876-6258
Rússia, Moscow

E. Orlova

Penza Institute for Postgraduate Medical Education – a Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID ID: 0000-0002-3902-2018
Rússia, Penza

D. Sychev

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID ID: 0000-0002-4496-3680
Rússia, Moscow

Bibliografia

  1. Liva G.A., Karatzanis A.D., Prokopakis E.P. Review of Rhinitis: Classification, Types, Pathophysiology. J Clin Med. 2021;10(14):3183. doi: 10.3390/jcm10143183.
  2. Thanaviratananich S., Cho S.H., Ghoshal A.G., et al. Burden of respiratory disease in Thailand: Results from the APBORD observational study. Medicine (Baltimore). 2016;95(28):e4090. doi: 10.1097/MD.0000000000004090.
  3. Tiligada E., Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020;177(3):469–89. doi: 10.1111/bph.14524.
  4. Карева Е.Н. Выбор антигистаминного препарата: взгляд фармаколога. Русский медицинский журнал. 2016;(12):811–6. [Kareva E.N. T he choice of an antihistamine drug: a pharmacologist’s point of view. Russkii meditsinskii zhurnal. 2016;(12):811–16. (In Russ.)].
  5. Bousquet J., Khaltaev N., Cruz A.A., et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma “epidemic”. Allergy. 2009;64:969–77. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63(Suppl. 86):8–160.
  6. URL: https://grls.rosminzdrav.ru/Default.aspx (по данным официальных ИМП Кестин, ИМП от 02.02.2023, Никсар, ИМП от 29.04.2022, Зодак, таб, ИМП от 30.05.2022).
  7. Официальная инструкция к препарату фенкарол. Государственный реестр лекарственных средств (rosminzdrav.ru) (дата обращения 26.04.2023). [Official instructions for the drug fenkarol. State Register of Medicines (rosminzdrav.ru) (accessed 04/26/2023). (In Russ.)].
  8. Bukovskis M., Tirzшte M., Strazda G., et al. H1-antihistamines suppress wheal-and-flare reaction and skin blood perfusion measured быby laser doppler flowmetry: randomized, double-blind, placebo-controlled, crossover design study. Proceed Latvian Acad Sci. 2010; 64(5/6):175–81.
  9. Clinical study report. Quinta No. 741/19 A Phase I, open-label study in healthy male and female subjects under fed condition to assess the pharmacokinetics of Fenkarol 10 mg and 50 mg tablets after single dose oral administration using a randomised, two-arm, parallel-group design and to investigate the multiple-dose pharmacokinetics of Fenkarol 50 mg administered orally after reaching steady state. Date of the Report: December 22, 2021. EudraCT number: 2019-004032-40. Data on file.
  10. Орлов Е.В., Меркулова Т.Б., Коннов П.Е. Клинический опыт применения антигистаминных производных хинуклидина в комплексной терапии зудящих дерматозов. Клиническая дерматология и венерология. 2014;12(6):74–81. [Orlov E.V., Merkulova T.B., Konnov P.E. Clinical experience with the use of antihistamine derivatives of quinuclidine in the complex therapy of pruritic dermatoses. Klinicheskaya dermatologiya i venerologiya. 2014;12(6):74–81. (In Russ.)].
  11. Лусс Л.В., Ильина Н.И. Антигистаминные препараты в общеклинической практике: Вопросы и ответы. В помощь практическому врачу. 2017. 184 с. [Luss L.V., Ilyina N.I. Antihistamines in general clinical practice: Questions and answers. To help the practical doctor. 2017. 184 p. (In Russ.)].
  12. Феденко Е.С. Фенкарол в комплексной терапии атопического дерматита и хронической крапивницы. Аллергия, астма и клиническая иммунология. 2003;(6):10–2. [Fedenko E.S. Fenkarol in the complex therapy of atopic dermatitis and chronic urticaria. Allergiya, astma i klinicheskaya immunologiya. 2003;(6):10–2. (In Russ.)].
  13. Гущин И.С., Каминка М.Э. Фенкарол антигистаминный препарат. Значение в современной клинической практике и рекомендации по применению. М, 2009. 32 с. [Gushchin I.S., Kaminka M.E. Phencarol is an antihistamine drug. Significance in modern clinical practice and recommendations for use. M, 2009. 32 p. (In Russ.)].
  14. Машковский М.Д., Мутина Е.С., Каминка М.Э. Фенкарол и его применение в терапии аллергических заболеваний. Клиническая медицина. 1978;58(11):22–7. [Mashkovsky M.D., Mutina E.S., Kaminka M.E. Phenkarol and its use in the treatment of allergic diseases. Klinicheskaya meditsina. 1978;58(11):22–7. (In Russ.)].
  15. Makarov L., Balykova L., Soldatova O., et al. The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial. Am J Ther. 2010;17(4):396–401. doi: 10.1097/MJT.0b013e3181a86987.
  16. Солдатова О.Н., Балыкова Л.А., Макаров Л.М. и др. Эффективность фенкарола в сочетании с традиционными противоаритмическими средствами при экстрасистолии у детей. Вестник РУДН. Серия Медицина. 2008;(3):46–51. [Soldatova O.N., Balykova L.A., Makarov L.M. et al. Efficiency of fencarol in combination with traditional antiarrhythmic drugs in extrasystole in children. Vestnik RUDN. Seriya Meditsina. 2008;(3):46–51. (In Russ.)].
  17. Лукьянов А.М., Музыченко А.П. Эффективность фенкарола в терапии лекарственно-индуцированных реакций на коже. Дерматовенерология. Косметология. 2016;2(2) [ Lukyanov A.M., Muzychenko A.P. Efficacy of phencarol in the treatment of drug-induced skin reactions. Dermatovener-ologiya. Kosmetologiya. 2016;2(2). (In Russ.)].
  18. Отчет о клиническом испытании препарата Фенкарол (хифенадина гидрохлорид) у пациентов с крапивницей (АО «Олайнфарм», Латвия). [Report on a clinical trial of Phencarol (chifenadine hydrochloride) in patients with urticaria (JSC Olainfarm, Latvia). (In Russ.)].
  19. Каминка М.Э. Экпериментальное и клиническое изучение нового противогистаминного препарата Фенкарол. Новые фармакологическое препараты. Сборник научных трудов ВНИХФИ. Выпуск 9. Под ред. М.Д. Машковского. 1982. С. 135–53. [Kaminka M.E. Experimental and clinical study of a new antihistamine drug Fenkarol. New pharmacological preparations. Collection of scientific papers VNIHFI. Issue 9. Ed. by M.D. Mashkovsky. 1982. P. 135–53. (In Russ.)].
  20. Никифорова Г.Н. и др. Аллергический ринит. Проблемы ведения пациентов. Русский медицинский журнал. 2018;8(I):46–5. [Nikiforova G.N. et al. Allergic rhinitis. Problems of patient management. Russkii meditsinskii zhurnal. 2018;8(I):46–5. (In Russ.)].

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies